Lindsey Shapiro, PhD,  science writer—

Regulators in the U.K. have approved UCB’s Rystiggo (rozanolixizumab) as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are positive for antibodies that target the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK). The decision from the Medicines and Healthcare products Regulatory Agency (MHRA) comes…

Clinical responses to the approved generalized myasthenia gravis (gMG) therapy Zilbrysq (zilucoplan) have now been sustained for more than a year among adults given long-term treatment, according to interim analyses of the Phase 3 RAISE-XT open-label extension (OLE) study. For patients who switched from a placebo in earlier clinical…

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) consistently reduced disease severity and improved quality of life across treatment cycles among adults with generalized myasthenia gravis (gMG) in an open-label extension study. With each monthlong cycle of the injectable therapy, most patients achieved a clinically meaningful reduction in the severity…

Curcumin therapy — treatment with the traditional Asian medicine, which is the main ingredient in the spice turmeric — was found to ease disease severity in a mouse model of myasthenia gravis (MG). Use of curcumin, a bright yellow chemical produced by plants, also was shown to normalize microbial…

Both high-dose intravenous methylprednisolone (IVMP) and tacrolimus effectively reduced symptom severity in patients with ocular myasthenia gravis (OMG) who failed to respond to oral steroids, a study shows. IVMP began to work quickly and more patients on it achieved a clinically meaningful treatment response over six months. “Both IVMP…

Repeat cycles of Vyvgart (efgartigimod alfa-fcab) led to consistent clinical improvements among generalized myasthenia gravis (gMG) patients, regardless of whether they were positive for antibodies against the acetylcholine receptor, according to interim findings from the ADAPT+ extension study. Given the variability in how many treatment cycles each patient…

The European Commission has approved Rystiggo (rozanolixizumab) as an add-on to standard therapy for the treatment of certain adults with generalized myasthenia gravis (gMG), closely following its clearance of Zilbrysq (zilucoplan) as an add-on treatment last month. These medications are sold by the biopharma company UCB.

Both propofol and sevoflurane — two types of agents for anesthesia management — were found to be safe and effective when used without muscle relaxants in myasthenia gravis (MG) patients undergoing surgery to remove the thymus gland. These findings, involving patients at a hospital in Vietnam, highlight what researchers…

People living with generalized myasthenia gravis (gMG) in the U.S. who experience certain barriers to healthcare reported major economic concerns in a new patient survey. These patients highlighted issues related to managing funds for emergency care, loss of income, and other non-medical expenses as contributing to a greater economic…

Daily treatment with zilucoplan was tied to meaningful reductions in symptom severity among the subgroup of Japanese generalized myasthenia gravis (gMG) patients who participated in the Phase 3 RAISE clinical trial, according to new subgroup analyses. The data add to accumulating trial evidence that the UCB therapy…